Table 2 Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023
From: Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Drug name | Format | Specificity | Indication | Clinical trial | Phase | Sponsor |
|---|---|---|---|---|---|---|
Plamotamab (XmAb13676) | XmAb Fab-Fc-scFv | CD20/CD3 | NHL, CLL | NCT02924402 | 1 | Xencor |
GB261 | Hz IgG1-based | CD20/CD3 | NHL, CLL | NCT04923048 | 1/2 | Genor Biopharma |
CM355 | NA | CD20/CD3 | NHL | NCT05210868 | 1/2 | Beijing InnoCare |
JS203 | NA | CD20/CD3 | NHL | NCT05618327 | 1 | Shanghai Junshi Bioscience |
IGM-2323 (imvotamab) | IgM-based 10 + 1 | CD20/CD3 | NHL | NCT04082936 | 1/2 | IGM Biosciences |
TQB2934 | IgG1-based | BCMA/CD3 | MM | NCT05646758 | 1 | Chia Tai Tianqing Pharma |
Abbv-383 (TNB-383B) | Hu IgG4-based | BCMA/CD3 | MM | NCT03933735 | 1/2 | AbbVie |
Alnuctamab (CC-93269) | Hz 2 + 1VH−VL± CrossMab | BCMA/CD3 | MM | NCT03486067 | 1 | Celgene (BMS) |
REGN5459 | mAb human VelociBi | BCMA/CD3 | MM | NCT04083534 | 1/2 | Regeneron |
EMB-06 | 2 + 2 CrossMab FIT-Ig | BCMA/CD3 | MM | NCT04735575 | 1/2 | EpimAb Shangai |
Forimtamig (RG6324) | Hz 2 + 1VH-VL ± CrossMab | GPRC5D/CD3 | MM | NCT04557150 | 1 | Roche |
RO7443904, RG6333 | 1 + 1 IgG1-based | CD19/CD28 | NHL | NCT05219513 | 1 | Roche |
Englumafusp α (RO7227166, RG6076) | 4-1BBL-anti- CD19 IgG1 fusion | CD19/CD137 | NHL | NCT04077723 | 1 | Roche |
GNR-084 | BiMS format | CD19/CD3 | B-ALL | NCT04601584 | 1/2 | GENERIUM |
TNB-486 | Hu IgG4-based | CD19/CD3 | NHL | NCT04594642 | 1 | TeneoTwo |
CLN-049 | Hz IgG1-like (+ 2 scFv), homodimer | FLT3/CD3 | AML, MS | NCT05143996 | 1 | Cullinan Oncology |
MGD024 | DART-Fc | CD123/CD3 | AML | NCT05362773 | 1 | MacroGenics |
APVO436 | ADAPTIR | CD123/CD3 | AML, MDS | NCT03647800 | 1 | Aptevo |
IGM-2644 | IgM-based 10 + 1 | CD38/CD3 | MM | NCT05908396 | 1 | IGM Biosciences |
ISB 1342 | BEAT 1.0 | CD38/CD3 | MM | NCT03309111 | 1 | Ichnos Sciences |
Y150 | YBODY (scFv-Fab-Fc) | CD38/CD3 | MM | NCT05011097 | 1 | Wuhan YZY Biopharma |
XmAb18968 | Bispecific Fc domains | CD38/CD3 | AML, T-ALL, T-LBL | NCT05038644 | 1 | IST |
SLAMF7 BATs | Chemically Hetero-conjugated | SLAMF7/CD3 | MM | NCT04864522 | 1 | University of Virginia |
Cevostamab (RG6160, BFCR4350A) | 1 + 1 CrossMab | FCRH5/CD3 | MM | NCT03275103 | 1 | Genentech/Roche |
NCT05535244 | 1/2 | |||||
JNJ-75348780 | NA | CD22/CD3 | NHL, CLL | NCT04540796 | 1 | Janssen |
ATG-101 | NA | PD-L1/CD137 | NHL | NCT04986865 | 1 | Antengene |
ONO-4685 | NA | PD-1/CD3 | T cell lymphoma | NCT05079282 | 1/2 | Ono Pharmaceutical |
NVG-111 | Tandem scFv | ROR1/CD3 | CLL, MCL | NCT04763083 | 1 | NovalGen |
SAR442257 | CODV-Fab | CD38/CD3/CD28 | MM, NHL | NCT04401020 | 1 | Sanofi |
HPN217 | TriTAC | BCMA/HSA/CD3 | MM | NCT04184050 | 1 | Harpoon Therapeutics |
ISB 2001 | TREAT | BCMA/CD38/CD3 | MM | NCT05862012 | 1 | Ichnos Sciences |
CMG1A46 | TRIAD IgG-like 1:(1 + 1) | CD19/CD20/CD3 | NHL, ALL | NCT05348889 | 1 | Chimagen |
JNJ-79635322 | Undisclosed | Undisclosed | MM | NCT05652335 | 1 | Janssen |
JNJ-80948543 | IgG1-based Fab-scFv | CD79b/CD20/CD3 | NHL, CLL | NCT05424822 | 1 | Jansen |
Emfizatamab (GNC-038) | NA | CD3/CD137/PD-L1/CD19 | NHL | NCT04606433 | 1 | Sichuan Baili Pharmaceutical |
NCT05623982 | 1/2 | |||||
MP0533 | DARPin | CD33/CD123/ CD70/CD3 | AML, MDS | NCT05673057 | 1/2 | Molecular Partners |